共 57 条
[1]
Deane KD(2021)Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift Arthritis Rheumatol. 73 181-93
[2]
Holers VM(2012)EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis Ann. Rheum. Dis. 71 638-41
[3]
Gerlag DM(2013)Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease Arthritis Rheum. 65 2243-52
[4]
Demoruelle MK(2003)Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum. 48 2741-9
[5]
Rantapaa-Dahlqvist S(2004)Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum. 50 380-6
[6]
Nielen MM(2017)The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population Rheumatology 56 2229-36
[7]
Gan RW(2015)Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study Ann. Rheum. Dis. 74 1659-66
[8]
Rakieh C(2019)Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study Ann. Rheum. Dis. 78 179-85
[9]
Gerlag DM(2019)Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol Trials 20 283-94
[10]
Al-Laith M(2022)Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial Lancet 400 3161-72